Holds one active US DMF and one valid CEP for omeprazole, filing since 2023. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 6 markets.
Holds 2 active US DMFs and 12 valid CEPs for omeprazole, filing since 1998. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 34 markets.
Holds 5 active US DMFs and 3 valid CEPs for omeprazole, filing since 1998. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 26 markets.
Holds 2 active US DMFs and one valid CEP for omeprazole, filing since 1997. Its 2023 FDA inspection closed as VAI, and its GMP is recognised in 37 markets.
Holds one active US DMF and 2 valid CEPs for omeprazole, filing since 2008. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 25 markets.
Holds 4 active US DMFs and 2 valid CEPs for omeprazole, filing since 2017. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 7 markets.
Holds 2 active US DMFs and one valid CEP for omeprazole, filing since 2008. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 15 markets.
Holds one active US DMF and one valid CEP for omeprazole, filing since 2009. Its 2019 FDA inspection closed as NAI.
Holds 3 active US DMFs and 4 valid CEPs for omeprazole, filing since 2009. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 2 markets.
Holds one valid CEP for omeprazole, filing since 2025. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 6 markets.
Holds 6 active US DMFs for omeprazole, filing since 2000. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 6 markets.
Holds one valid CEP for omeprazole, filing since 2013. Its 2024 FDA inspection closed as NAI, and its GMP is recognised in 8 markets.
Holds one active US DMF for omeprazole, filing since 2008. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 30 markets.
Holds 8 active US DMFs for omeprazole, filing since 2015. Its 2024 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds one active US DMF for omeprazole, filing since 2004. Its 2022 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Holds 2 active US DMFs for omeprazole, filing since 2015. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds 2 active US DMFs for omeprazole, filing since 2013. Its 2025 FDA inspection closed as NAI.
Holds 4 active US DMFs for omeprazole, filing since 2011. Its 2022 FDA inspection closed as NAI.
Holds one active US DMF for omeprazole, filing since 1995. Its GMP is recognised in 1 market.
Holds 2 active US DMFs and 3 valid CEPs for omeprazole, filing since 2007. Its 2025 FDA inspection closed as VAI.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
Contract manufacturers make to order rather than holding their own filing for this molecule.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free| Year | Median | Exporters |
|---|---|---|
| 2026 YTD | $8.91 | 64 |
| 2025 | $13.35 | 168 |
| 2024 | $16.00 | 118 |
| 2023 | $12.21 | 160 |
US dollars per kilogram, customs export unit values.